

## SCOR GROUP 2013 results

SCOR posts record net income of EUR 549 million and an ROE of 11.5% in 2013, and proposes a dividend of EUR 1.30 per share

**SCOR**

## Notice

---

Certain statements contained in this presentation are forward-looking statements, of necessity provisional, that are based on risks and uncertainties that could cause actual results, performance or events to differ materially from those in such statements.

Undue reliance should not be placed on such statements because by their nature they are subject to known and unknown risks and uncertainties.

As a result of the extreme and unprecedented volatility and disruption related to the financial crisis, SCOR is exposed to significant financial, capital market and other risks, including movements in interest rates, credit spreads, equity prices, currency movements, changes in government or regulatory practices, changes in rating agency policies or practices, and the lowering or loss of financial strength or other ratings.

Additional information regarding risks and uncertainties that may affect SCOR's business is set forth in the 2012 reference document filed 6 March 2013 under number D.13-0106 with the French Autorité des marchés financiers (AMF) posted on SCOR's website [www.scor.com](http://www.scor.com) and (ii) in the reference document for 2013 expected to be filed with the AMF on 5 March 2014 (collectively the "Document de Référence") thereafter posted on SCOR's website. SCOR undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise.

SCOR's financial information is prepared on the basis of IFRS and interpretations issued by the IASB and endorsed by the European Union. The quarterly financial information does not constitute a set of financial statements for an interim period as defined by IAS 34 "Interim Financial Reporting". The financial results for the full year 2013 included in this presentation have been audited by SCOR's independent auditors.

Prior year comparatives have been restated retrospectively due to the adoption of IAS 19 – Employee Benefits (revised). Restated figures included in this presentation are identified as such.

Certain prior year balance sheet items have been reclassified to be consistent with the current year presentation.

Numbers presented throughout this report may not add up precisely to the totals in the tables and text. Percentages and percent changes are calculated on complete figures (including decimals); therefore the presentation might contain immaterial differences in sums and percentages and between slides due to rounding.

## In the presentation two sets of financial data are used: published accounts & pro-forma information

---

### Audited published accounts: Full year and 4th quarter accounts

- ❑ Reflect Q4 2013 figures for Generali U.S. from acquisition date, (01/10-31/12) of full consolidation
- ❑ Audited annual accounts have been prepared reflecting the Generali U.S. from acquisition date
- ❑ Prior year comparatives do not include Generali U.S.

### Unaudited pro-forma information: Full year information

- ❑ Following IFRS 3 guidance – an acquirer shall disclose information that enables users of its financial statements to evaluate the nature and financial impact of business combinations that were effected during the period. In addition, in accordance with AMF rules, pro forma financial information can be provided on a voluntary basis.
- ❑ The unaudited pro-forma financial information as of 31 December 2013 is presented to illustrate the effects on SCOR's income statement of the Generali U.S. acquisition as if the acquisition had taken place on 1 January 2013. A pro forma income statement is also included in the 2013 DDR.
- ❑ No prior year comparatives presented

SCOR posts record net income of EUR 549 million and an ROE of 11.5% in 2013, and proposes a dividend of EUR 1.30 per share

---

1	SCOR has the right strategy to deliver superior shareholder value
2	Full year 2013 results
3	SCOR's strategy fits well with the current financial environment and market themes

## In 2013 SCOR's unique strategy has been consistently applied...



...and its execution has delivered a high level of profitability & solvency, recognized by financial markets and key stakeholders

## SCOR executes a strong performance in 2013

- 2013 stock price increases by 30% and the TSR<sup>1)</sup> reaches 36%
- S&P raises SCOR to A+ positive outlook

### On Profitability ✓

Target: 1,000 bps above RFR <sup>2)</sup>	Actual: 1,129 bps above RFR <sup>2)</sup>
<ul style="list-style-type: none"> <li>□ SCOR Global P&amp;C records successful 2013 renewals and generates 8.3%<sup>3)</sup> growth with technical profitability already trending towards the new strategic plan</li> <li>□ SCOR Global Life acquires Generali US with a gain on purchase of € 183 million and shows strong growth (14.5%<sup>3)</sup>) and technical performance trending towards the Optimal Dynamics plan</li> <li>□ SCOR Global Investments demonstrates active asset portfolio management, including real estate acquisitions (MRM)</li> <li>□ Invested assets increase whilst limiting the potential for unrealized losses with its short durations should interest rates suddenly increase</li> </ul>	

### On Solvency ✓

Target: Solvency Ratio <sup>4)</sup> in the 185%-220% range	2013: 221% <sup>5)</sup>
<ul style="list-style-type: none"> <li>□ SCOR unveils a new &amp; innovative capital management policy at its Investors' Day, with a clear escalation framework</li> <li>□ SCOR enters into an extreme mortality risk transfer contract with Atlas IX providing USD 180 million of extreme mortality protection</li> <li>□ SCOR places a fully collateralized sidecar, Atlas X, which provides the Group with a three-year capacity of USD 55.5 million</li> <li>□ SCOR launches a contingent capital facility providing € 200 million coverage in case of extreme natural catastrophe or mortality events</li> <li>□ SCOR issues CHF 250 million perpetual subordinated notes with a coupon set to 5%</li> </ul>	

1) *TSR: Total Shareholder Returns: represents the share price appreciation + dividends paid out*

2) *Three-month risk-free rate*


3) *At constant exchange rates*

4) *As per Group Internal Model, ratio of Available Capital over SCR*

5) *Projected solvency ratio including Generali US*

## Management proposal of 2013 dividend of € 1.30<sup>1)</sup> per share confirms SCOR's superior risk/return value proposition to its shareholders

SCOR offers strong returns with low volatility to its shareholders, in addition to a consistent dividend policy



	'05	'06	'07	'08	'09	'10	'11	'12	'13 <sup>1)</sup>
<b>Dividends paid, € m</b>	48	94	144	144	179	201	203	223	241
<b>DPS, €</b>	0.5	0.8	0.8	0.8	1.0	1.1	1.1	1.2	1.3
<b>Payout %<sup>2)</sup></b>	37%	37%	35%	45%	48%	48%	62%	53%	44%

- ❑ SCOR has paid stable or increasing dividends since 2005
- ❑ Proposed cash dividend of € 1.30<sup>1)</sup> per share, representing a payout ratio of 44%<sup>2)</sup>
- ❑ ~ € 1.5 billion<sup>1)</sup> of dividends distributed over the last nine years, with strong payout ratio even in years with high levels of natural catastrophes (2005, 2010 and 2011) and financial stress (2008), demonstrating SCOR's shock-absorbing capacity
- ❑ SCOR's dividend policy is supported by strong operating cashflow generation from both divisions: more than € 2.1 billion over the last 3 years



Source Factset. Peers shown in this analysis are Axis, Everest Re, Hannover Re, Munich Re, Partner Re, Renaissance Re and Swiss Re  
 1) 2013 dividend subject to approval of the Shareholders' Annual General Meeting on May 6, 2014  
 2) Payout ratio calculated as "Total dividends paid" over "Consolidated Net Income"  
 3) TSR: Total Shareholder Returns, represents the share price appreciation + dividends paid out

SCOR posts record net income of EUR 549 million and an ROE of 11.5% in 2013, and proposes a dividend of EUR 1.30 per share

---

- |   |  |
|---|--|
| 1 | SCOR has the right strategy to deliver superior shareholder value                  |
| 2 | Full year 2013 results   |
| 3 | SCOR's strategy fits well with the current financial environment and market themes |



## SCOR delivers strong 2013 financials

- ❑ **Gross written premium growth of 7.8% (11.5% at constant exchange rates) in 2013 compared to 2012**, driven by healthy SCOR Global P&C renewals, by major new contracts signed by SCOR Global Life and by the Generali US contribution<sup>1)</sup>
- ❑ **2013 record net income of € 549 million** with an 11.5% return on equity (ROE); 12.4% excluding equity impairments
- ❑ **2013 operating cashflow of € 897 million** (+18% compared to 2012), with strong contributions from SCOR Global P&C and SCOR Global Life

### SCOR Global P&C

- ❑ **Strong growth of 8.3% at constant FX** in 2013
- ❑ SGPC's **2013 net combined ratio at 93.9%**<sup>2)</sup> compared to 94.1% in 2012, in line with 2013 expectations as indicated in Optimal Dynamics

### SCOR Global Life

- ❑ **Excellent growth of 14.5% at constant FX**, supported by Generali US acquisition and new contracts signed in Asia, UK and the Iberian Peninsula
- ❑ SGL's **2013 technical margin stands at 7.3%**<sup>3)</sup> compared to 7.7%<sup>3)</sup> in 2012, in line with 2013 expectations

### SCOR Global Investments

- ❑ In 2013, SGI has maintained its **prudent asset management**, and started to slightly increase the duration of the portfolio
- ❑ **Ongoing return on invested assets stands at 3.1%** (excluding equity impairments) thanks to SGI's active portfolio management

**In 2013 SCOR delivers strong profitability, with an ROE 1 129 bps above risk-free rate<sup>4)</sup>  
(1 219 bps excluding equity impairments)**

1) Acquired on October 1<sup>st</sup> 2013

2) See Appendix E, page 43 for detailed calculation of the combined ratio

3) 2012 includes 0.3 pts. of non-recurring items linked to GMDB run-off portfolio reserve release and 2013 includes 0.1 pt.; See Appendix F, page 46 for detailed calculation of the technical margin

4) Three-month risk-free rate

## SCOR 2013 financial details (published only)

<i>in € millions (rounded)</i>		2013	2012	Variation at current FX	Variation at constant FX
<b>Group</b>	<b>Gross written premiums</b>	10 253	9 514	7.8%	11.5%
	<b>Net earned premiums</b>	9 066	8 399	7.9%	10.3%
	<b>Operating results</b>	783 <sup>5)</sup>	632	23.9%	
	<b>Net income</b>	549	418	31.3%	
	<b>Group cost ratio<sup>1)</sup></b>	5.1%	5.3%	-0.2 pts	
	<b>Investment income</b>	512 <sup>6)</sup>	566	-9.5%	
	<b>Net return on invested assets w/o equity impairments<sup>2)</sup></b>	3.1%	3.5%	-0.4 pts	
	<b>Net return on invested assets (with equity impairments)<sup>2)</sup></b>	2.6%	3.0%	-0.4 pts	
	<b>Annualized ROE w/o equity impairments</b>	12.4%	10.2% <sup>7)</sup>	2.2 pts	
	<b>Annualized ROE</b>	11.5%	9.1% <sup>7)</sup>	2.4 pts	
	<b>EPS (€)</b>	2.96	2.28	29.8%	
	<b>Book value per share (€)</b>	26.64	26.16 <sup>7)</sup>	1.8%	
	<b>Operating cash flow</b>	897	761	17.9%	
<b>P&amp;C</b>	<b>Gross written premiums</b>	4 848	4 650	4.3%	8.3%
	<b>Combined ratio<sup>3)</sup></b>	93.9%	94.1%	-0.2 pts	
<b>Life</b>	<b>Gross written premiums</b>	5 405	4 864	11.1%	14.5%
	<b>Life technical margin<sup>4)</sup></b>	7.3%	7.7%	-0.4 pts	



1) See Appendix D, page 41 for detailed calculation of the cost ratio  
 2) See Appendix G, page 51 for detailed calculation of the return on invested assets  
 3) See Appendix E, page 43 for detailed calculation of the combined ratio  
 4) See Appendix F, page 46 for detailed calculation of the technical margin

5) Acquisition related expenses and gain from bargain purchase are reported within operating results, under "operating results before impact of acquisitions", to conform to the presentation in the 2013 Document de Référence, see Appendix A, page 28

6) Includes MRM goodwill net of acquisition costs, see page 52 for details

7) BVPS is adjusted due to the retrospective application of IAS 19 "revised", Q4 2012 published BVPS amounts to € 26.18, annualized ROE amounts to 9.1% and annualized ROE w/o equity impairments amounts to 10.2%

## Generali US acquisition makes a substantial contribution to the 2013 published and pro-forma<sup>1)</sup> accounts

### Generali US 2013 contribution to published accounts

<i>In € millions (rounded)</i>	
Purchase price	587 <sup>2)</sup>
- Net assets acquired	784 <sup>2)</sup>
<hr/>	
Profit from a bargain purchase (badwill)	197
- Transaction costs (net of tax)	14 <sup>3)</sup>
<hr/>	
<b>Gain on purchase</b>	<b>183</b>
<hr/>	
<b>Operating performance (net of tax)</b>	<b>10<sup>4)</sup></b>
<hr/>	
<b>Net Income</b>	<b>193</b>

- ❑ Strong published net income contribution from Generali US (€ 193 million), with a gain on purchase of € 183 million and an operating performance net of tax of € 10 million in Q4 2013
- ❑ Published contribution of Generali US business amounts to gross written premiums (GWP) of € 209 million with a technical margin of 7.7%
- ❑ On a pro-forma basis, GWP for Generali US amounts to € 854 million, with a technical margin of 7.5%

### 1 October – 31 December Generali US results

<i>In € millions (rounded)</i>	
Gross written premiums (GWP)	209
<b>Technical margin</b>	<b>7.7%</b>

### Pro-forma Q4 YTD Generali US results

<i>In € millions (rounded)</i>	
Gross written premiums (GWP)	854
<b>Technical margin</b>	<b>7.5%</b>

1) For more details on published and pro-forma accounts see Appendix A & B, from page 27


2) FX used for PGAAP accounting: 1 USD = 0.7402 EUR

3) Transaction costs incurred in 2013

4) Operating performance net of tax reflects Q4 2013 figures for Generali US from acquisition date, i.e. 1 quarter of full Generali US consolidation (from 01/10/2013 to 31/12/2013)

# SCOR's successful Generali US acquisition and integration enlarges the dimension of the Group

## The transaction enlarges the dimensions of the whole SCOR group...




Thanks to the Generali US acquisition, SCOR Global Life (SGL) becomes the leading reinsurer in the US<sup>3)</sup>


The integration is ahead of schedule with business organization, pricing processes and HR system in place

No client attrition, or key talent loss, confirm SCOR's excellent track record when integrating new acquisitions

## ...with SGLA<sup>2)</sup> becoming the leader in the US life reinsurance market



## In 2013, SCOR has positive shareholders' equity development with an increased BVPS at € 26.64 after distribution of € 223 million of cash dividends



1) The calculation of the leverage ratio excludes accrued interest from debt and includes the effects of the swaps related to the CHF 650 million (issued in 2011), CHF 315 million (issued in 2012) and CHF 250 million (issued in 2013) subordinated debt issuances

2) Shown SHE is adjusted due to the retrospective application of IAS 19 "revised": (i) Q4 2012 published SHE amounted to € 4810 million (ii) shown book value per share and financial leverage ratio have been recalculated – published numbers for financial leverage and BVPS were 19.9% and € 26.18 respectively

3) Excluding minorities. Refer to page 40 for the detailed calculation of the book value per share



4) Variation of unrealized gains/losses on AFS securities, net of shadow accounting and taxes, see Appendix G, page 64

## € 897 million of net operating cash flow generated in 2013, +18% compared to 2012

<i>In € millions (rounded)</i>	2013	2012
<b>Cash and cash equivalents at 1 January</b>	<b>1 466</b>	<b>1 281</b>
Net cash flows from operations, of which:	897	761
<i>SCOR Global P&amp;C</i>	601	534
<i>SCOR Global Life</i>	296	227
Net cash flows used in investment activities <sup>1)</sup>	-666	-438
Net cash flows used in financing activities <sup>2)</sup>	-107	-146
Effect of changes in foreign exchange rates	-76	8
<b>Total cash flow</b>	<b>48</b>	<b>185</b>
<b>Cash and cash equivalents at 31 December</b>	<b>1 514</b>	<b>1 466</b>
Short-term investments (i.e. T-bills less than 12 months) classified as "other loans and receivables" <sup>3)</sup>	606	1 269
<b>Total liquidity</b>	<b>2 120</b>	<b>2 735</b>

- Business model delivers a record operating cash flow of € 897 million as at 31 December 2013, increasing by 18% compared to 2012 (€ 761 million), with contributions from both business engines
- Cash and short-term investments position stands at € 2.1 billion as of Q4 2013, compared to € 2.7 billion as of Q4 2012
- Approximately € 6.1 billion (including cash and short-term investments) of liquidity expected to be generated within the next 24 months

# SGPC continues to combine growth and technical profitability, while performing well towards the Optimal Dynamics objectives and assumptions




- 2013 gross written premiums growth of 4.3% (+8.3% at constant exchange rates);** in view of the impact of the strong exchange rate headwinds, this growth rate compares favourably with the ~6% full year premium growth expectations post-1/1/2013 renewal and the 5.5% organic (+ 3% from initiatives) annual premium growth assumption in Optimal Dynamics
- Technical results significantly better than the Strong Momentum assumption** and within the Optimal Dynamics range, **with a net combined ratio of 93.9%<sup>1)</sup>**
  - A net attritional loss ratio of 57.7%**, including 0.7% impact of € 31 million reserve release<sup>3)</sup> in Q2 2013; the 58.4% “normalized” attritional ratio (vs. 60.1%<sup>2)</sup> in 2012) positions SGPC well in the early part of Optimal Dynamics versus the assumed trend towards 57% over the 3 years of the plan
  - Nat cat net losses of 6.4%**, consistent with the transition towards the 7% budget going forward into Optimal Dynamics
  - Commissions of 23.1%**, reflecting the growth of the Lloyd’s business

1) See Appendix E, page 43 for detailed calculation of the combined ratio  
 2) Including 2.2 pts of reserves released in Q4 2012, primarily from the Aviation and Inherent Defect Insurance (IDI) lines of business, the normalized attritional loss ratio was at 60.1%

3) Including 0.7 pts of reserves released in Q2 2013, primarily from the Property, Engineering and Aviation lines of business, the normalized attritional loss ratio is at 58.4%



# SGPC continues its strong organic-only growth and improving combined ratio trend, thanks to the active management of its well-diversified portfolio



1) See Appendix E, page 44 for detailed calculation of the normalized combined ratio



## SCOR Global Life combines a healthy technical margin with excellent growth, confirming the dynamism of the franchise




- In 2013, SCOR Global Life acquires Generali US and successfully captures opportunities in its “financial solutions” and longevity strategic segments contributing to **excellent 11.1% growth compared to 2012** (14.5% at constant exchange rates), driven by:
  - Generali US acquisition (+ €209 million)
  - Organic growth (10.2% at constant exchange rates and 6.8% at current exchange rates) with double-digit growth in the UK/Ireland, Asia and Spain and double-digit growth in longevity and financial solutions, partly offset by negative FX (€ 163 million) and selective decreases in the Middle East, France and the Nordic countries as well as in disability and personal accident
- **Strong technical margin of 7.3%<sup>2)</sup>** including non-recurring items (GMDB run-off portfolio reserve release), with the underlying performance trending towards Optimal Dynamics and reflecting the ongoing change in portfolio mix
- **Generali US acquisition (closed on 1<sup>st</sup> October) consolidates SGL's leading position in the US**

1) GMDB run-off portfolio reserve release

2) See Appendix F, page 46 for detailed calculation of the technical margin

# SCOR Global Life has a proven track record of strong growth, while delivering consistent profitability




1) Excluding US annuity business "IIC": Investors Insurance Corporation, a subsidiary sold in relation to SCOR's disposal of its US annuity business, see press release #22 of 19 July 2011  
2) Published figure of 7.7% includes 0.3 pts. from non-recurring items (GMDB reserve adjustment)

3) Published figures of 7.3% includes 0.1 pt. from non-recurring items (GMDB reserve adjustment)  
4) Pro-forma figures including Transamerica Re for the full year 2011  
5) Pro-forma GWP including Generali US for the full year 2013

# SCOR Global Investments delivers an ongoing return on invested assets of 3.1%

## Total invested assets <sup>1)</sup>: € 15.2 billion at 31/12/2013



## Return on invested assets <sup>1)3)</sup>

Year	Total invested assets	Return on invested assets
2012	€ 13 982 million	+3.0%
2013 (including equity impairments)	€ 15 187 million	+2.6%
2013 (excluding equity impairments)	€ 15 187 million <sup>4)</sup>	+3.1%



## Global Investments

- ❑ Total investments of € 23.4 billion, of which total invested assets of € 15.2 billion and funds withheld of € 8.2 billion
- ❑ Prudent investment strategy pursued in Q4 2013:
  - decreased liquidity (-4 pts.)
  - slightly increased fixed income portfolio duration at 3.4 years<sup>5)</sup>
  - high quality fixed income portfolio maintained with an AA- average rating, no sovereign exposure to GIIPS<sup>6)</sup>
  - highly liquid investment portfolio, with financial cash flows<sup>7)</sup> of € 6.1 billion expected over the next 24 months
- ❑ Recurring ongoing performance:
  - investment income on invested assets of € 372 million for 2013, of which realized gains comprise € 130 million<sup>8)</sup>, offset by strict and unchanged amortization and impairment policy of € 97 million (of which € 64 million on equities)
  - ongoing return on invested assets for 2013 of 3.1% excluding equity impairments (2.6% including equity impairments)

1) Excluding funds withheld, technical items and accrued interest; details of total investment portfolio in Appendix G, page 48  
 2) See page 62 for details of the "Other investments" category  
 3) See full details on investment returns and income pages 51 and 52  
 4) Equity impairments are net asset value neutral

5) Of the fixed income portfolio; 2.5 year duration on invested assets  
 6) See Appendix G, page 53 for details of the government bond portfolio  
 7) Including cash, coupons and redemptions  
 8) See Appendix G, page 52 for details

## In line with Optimal Dynamics orientations, SCOR Global Investments is progressively rebalancing the investment portfolio

### The current macroeconomic outlook is slightly more positive, even if it remains uncertain

- ❑ Global economy is better oriented
- ❑ Distortion between market valuations and economic expectations is narrowing
- ❑ 2014 should be a year of differentiation in interest rates, the market having started to move away from pricing a “synchronized” exit by central banks, between early cycles countries (such as the UK and the US) and the Eurozone which is lagging behind
- ❑ Emerging and developing economies have very different vulnerabilities to a massive capital outflow
- ❑ China is facing a growing debt burden and recurring tensions in its financial system

#### Progressive and selective reallocation towards the strategic asset allocation




#### Progressive re-matching of the fixed income portfolio towards the target effective duration


##### Reallocation program

- ❑ 4 pts. of liquidity reinvested throughout Q4 2013, mainly in fixed income (government bonds and assimilated, covered bonds and agency MBS) and loans
- ❑ Selective increase of the duration in the GBP and USD buckets
- ❑ Ongoing reinvestment yield (~2.6%)<sup>1)</sup> above recurring yield (~2.2%)<sup>2)</sup>

##### Effective duration<sup>3)</sup>



##### RoIA vs. risk-free benchmark<sup>4)</sup>



1) As of 04/02/2014

2) 2013 income yield and FVI yield, excluding MRM badwill (19 bps. impact on 2013 RoIA), realized capital gains/losses, impairments and real estate amortization

3) Effective duration of the fixed income portfolio, excluding cash

4) 4 year risk-free rates, with actual currency split by year end into USD (USA), EUR (Germany) and GBP (UK)

SCOR posts record net income of EUR 549 million and an ROE of 11.5% in 2013, and proposes a dividend of EUR 1.30 per share

---


- 1 SCOR has the right strategy to deliver superior shareholder value
- 2 Full year 2013 results
- 3 SCOR's strategy fits well with the current financial environment and market themes

# SCOR's strategy is well positioned for the current financial environment and market themes

## Current financial environment and market themes



## SCOR's unique strategy addresses current market themes



## SCOR confirms “Optimal Dynamics” targets, balancing profitability and solvency, alongside a strong shareholder remuneration policy

### SCOR Two targets for the Optimal Dynamics plan


#### Profitability (ROE) Target

1 000 bps above risk-free<sup>1)</sup> rate over the cycle

#### Solvency Target

Solvency ratio<sup>2)</sup> in the 185% - 220% range

#### SCOR's dividend policy remains unchanged: between 2005 and 2013 it has paid out ~ € 1.5 billion<sup>3)</sup>



□ SCOR aims to remunerate shareholders through cash dividends

□ If relevant, SCOR does not exclude other means

□ Overall the Board will aim to maintain a minimum dividend payout of 35% over the cycle, while aiming for low volatility in the dividend per share (DPS) from year to year


1) 3-month risk-free rate

2) As per the Group Internal Model; it is the ratio of Available Capital over SCR (Solvency Capital Requirements); see page 21 of “Optimal Dynamics” for further details

3) 2013 dividend subject to approval of the Shareholders’ Annual General Meeting on May 6, 2014

## 2014 forthcoming events and Investor Relations contacts

### Forthcoming scheduled events



### In 2014 SCOR is scheduled to attend the following investor conferences

- HSBC, Paris (March 25)
- Morgan Stanley, London (March 26)
- JP Morgan, Amsterdam (May 13)
- Societe Generale, NYC (May 20)
- Societe Generale, Nice (May)
- Deutsche Bank, NYC (May 27)
- Commerzbank, London (June 4)
- Goldman Sachs, Madrid (June 12)
- BofAML, London (October 1)
- Berenberg, London (December)

### Contacts: [investorrelations@scor.com](mailto:investorrelations@scor.com)

#### **Antonio Moretti**

Investor Relations Director  
[amoretti@scor.com](mailto:amoretti@scor.com)  
+ 33 1 58 44 77 15

#### **Margaux Lascar**

Investor Relations Manager  
[mlascar@scor.com](mailto:mlascar@scor.com)  
+ 33 1 58 44 74 26

#### **Marine Collas**


Investor Relations Manager  
[mcollas@scor.com](mailto:mcollas@scor.com)  
+ 33 1 58 44 77 64

#### **Florent Defretin**

Investor Relations Analyst  
[fdefretin@scor.com](mailto:fdefretin@scor.com)  
+ 33 1 58 44 77 36



# The SCOR IR app puts SCOR at the fingertips of investors



- ✓ Home Page
- ✓ Latest press releases
- ✓ Financial communication
- ✓ Share price monitor
- ✓ Conference presentations
- ✓ Research Publications
- ✓ Push notifications
- ✓ Contacts



## APPENDICES

---

Appendix A	P&L
Appendix B	Balance sheet & Cash flow
Appendix C	Calculation of EPS, Book value per share and ROE
Appendix D	Expenses & cost ratio
Appendix E	P&C
Appendix F	Life
Appendix G	Investment
Appendix H	Debt
Appendix I	Estimated sensitivities on net income and shareholders' equity
Appendix J	Rating evolution
Appendix K	SCOR's strategy fits well with the current financial environment and market themes
Appendix L	Listing information
Appendix M	Awards

## Appendix A: Key adjustments between published results and pro-forma

<i>In € millions (rounded)</i>	SCOR standalone 2013	Impact of acquisition	Generali US 2013 operating performance	SCOR 2013 Published	Generali US Operating performance pro-forma adjustment	Transaction and restructuring costs adjustments	Investment income adjustment and debt interest	SCOR 2013 Pro-forma
	(1)	(2)	(3)	(A) = (1)+(2)+(3)	(5)	(6)	(7)	(B) = (A)+(5)+(6)+(7)
Gross written premiums	10 044	0	209	10 253	645	0	0	10 898
Net earned premium	8 885	0	181	9 066	558	0	0	9 624
Net technical result	728	0	14	742	41	0	0	783
Total net investment income	516	0	4	520	17	0	-3	534
Total expenses	-558	0	-6	-564	-21	0	0	-585
Current operating result	618	0	12	630	37	0	-3	664
Other operating expenses	-49	0	0	-49	0	0	0	-49
Operating result	569	0	12	581	37	0	-3	615
Financing expenses	-130	0	0	-130	0	0	-10	-140
Share in results of associates	-13	0	0	-13	0	0	0	-13
Acquisition-related expenses	-6	-19	0	-25	0	2	0	-23
Profit from bargain purchase	30 <sup>1)</sup>	197	0	227	0	0	0	227
Corporate income tax	-94	5	-2	-91	-6	-1	3	-95
<b>Group Net Income</b>	<b>356</b>	<b>183</b>	<b>10</b>	<b>549</b>	<b>31</b>	<b>1</b>	<b>-10</b>	<b>571</b>

- **Investment income:** for Generali US, assumed fully deployed portfolio from 1/1/13 until 1/10/13; used SCOR portfolio yield from acquisition date
- **Financing expenses:** adjusted to reflect 2013 CHF 250 million hybrid debt<sup>2)</sup> as if issued on 1/1/2013
- **Acquisition-related expenses:** costs related to the transaction and incurred in Q3 2013 have been reversed as if paid in 2012; integration costs have been added

## Appendix A: Consolidated statement of income, full year 2013, published

<i>In € millions (rounded)</i>	<b>SCOR standalone</b>	<b>Generali US standalone</b>	<b>2013 Published</b>	<b>2012 Published</b>
Gross written premiums	10 044	209	10 253	9 514
Change in gross unearned premiums	-75	0	-75	-147
Gross benefits and claims paid	-6 893	-161	-7 054	-6 613
Gross commissions on earned premiums	-1 910	-19	-1 929	-1 909
<b>Gross technical result</b>	<b>1 166</b>	<b>29</b>	<b>1 195</b>	<b>845</b>
Ceded written premiums	-1 095	-28	-1 123	-976
Change in ceded unearned premiums	11	0	11	8
Ceded claims	482	13	495	635
Ceded commissions	164	0	164	144
<b>Net result of retrocession</b>	<b>-438</b>	<b>-15</b>	<b>-453</b>	<b>-189</b>
<b>Net technical result</b>	<b>728</b>	<b>14</b>	<b>742</b>	<b>656</b>
Other income and expenses from reinsurance operations	-68	0	-68	-36
<b>Total other operating revenue / expenses</b>	<b>-68</b>	<b>0</b>	<b>-68</b>	<b>-36</b>
Investment revenues	302	4	306	317
Interests on deposits	176	0	176	202
Realized capital gains / losses on investments	130	0	130	161
Change in investment impairment	-97	0	-97	-86
Change in fair value of investments	15	0	15	8
Foreign exchange gains / losses	-10	0	-10	23
<b>Investment income</b>	<b>516</b>	<b>4</b>	<b>520</b>	<b>625</b>
Investment management expenses	-36	0	-36	-30
Acquisition and administrative expenses	-367	-6	-373	-349
Other current operating expenses	-155	0	-155	-177
Other current operating income	0	0	0	0
<b>Current operating results</b>	<b>618</b>	<b>12</b>	<b>630</b>	<b>689</b>
Goodwill – value changes	0	0	0	0
Other operating expenses	-49	0	-49	-50
Other operating income	0	0	0	6
<b>Operating results before impact of acquisitions</b>	<b>569</b>	<b>12</b>	<b>581</b>	<b>645</b>
Acquisition-related expenses	-6	-19	-25	-13
Gain on bargain purchase	30	197	227	0
<b>Operating results</b>	<b>593</b>	<b>190</b>	<b>783</b>	<b>632</b>
Financing expenses	-130	0	-130	-106
Share in results of associates	-13	0	-13	0
Corporate income tax	-94	3	-91	-108
<b>Consolidated net income</b>	<b>356</b>	<b>193</b>	<b>549</b>	<b>418</b>
of which non-controlling interests	0	0	0	0
<b>Group net income</b>	<b>356</b>	<b>193</b>	<b>549</b>	<b>418</b>

## Appendix A: Consolidated statement of income, full year 2013, pro-forma

<i>In € millions (rounded)</i>	SCOR standalone	Generali US standalone	Adjustments	2013 Pro-forma	2012 Published
Gross written premiums	10 044	209	645	10 898	9 514
Change in gross unearned premiums	-75	0	0	-75	-147
Gross benefits and claims paid	-6 893	-161	-517	-7 571	-6 613
Gross commissions on earned premiums	-1 910	-19	-60	-1 989	-1 909
<b>Gross technical result</b>	<b>1 166</b>	<b>29</b>	<b>68</b>	<b>1 263</b>	<b>845</b>
Ceded written premiums	-1 095	-28	-87	-1 210	-976
Change in ceded unearned premiums	11	0	0	11	8
Ceded claims	482	13	56	551	635
Ceded commissions	164	0	4	168	144
<b>Net result of retrocession</b>	<b>-438</b>	<b>-15</b>	<b>-27</b>	<b>-480</b>	<b>-189</b>
<b>Net technical result</b>	<b>728</b>	<b>14</b>	<b>41</b>	<b>783</b>	<b>656</b>
Other income and expenses from reinsurance operations	-68	0	0	-68	-36
<b>Total other operating revenue / expenses</b>	<b>-68</b>	<b>0</b>	<b>0</b>	<b>-68</b>	<b>-36</b>
Investment revenues	302	4	14	320	317
Interests on deposits	176	0	0	176	202
Realized capital gains / losses on investments	130	0	0	130	161
Change in investment impairment	-97	0	0	-97	-86
Change in fair value of investments	15	0	0	15	8
Foreign exchange gains / losses	-10	0	0	-10	23
<b>Investment income</b>	<b>516</b>	<b>4</b>	<b>14</b>	<b>534</b>	<b>625</b>
Investment management expenses	-36	0	-1	-37	-30
Acquisition and administrative expenses	-367	-6	-20	-393	-349
Other current operating expenses	-155	0	0	-155	-177
Other current operating income	0	0	0	0	0
<b>Current operating results</b>	<b>618</b>	<b>12</b>	<b>34</b>	<b>664</b>	<b>689</b>
Goodwill – value changes	0	0	0	0	0
Other operating expenses	-52	0	0	-52	-50
Other operating income	3	0	0	3	6
<b>Operating results before impact of acquisitions</b>	<b>569</b>	<b>12</b>	<b>34</b>	<b>615</b>	<b>645</b>
Acquisition-related expenses	-6	-19	2	-23	-13
Gain on bargain purchase	30	197	0	227	0
<b>Operating results</b>	<b>593</b>	<b>190</b>	<b>36</b>	<b>819</b>	<b>632</b>
Financing expenses	-130	0	-10	-140	-106
Share in results of associates	-13	0	0	-13	0
Corporate income tax	-94	3	-4	-95	-108
<b>Consolidated net income</b>	<b>356</b>	<b>193</b>	<b>22</b>	<b>571</b>	<b>418</b>
of which non-controlling interests	0	0	0	0	0
<b>Group net income</b>	<b>356</b>	<b>193</b>	<b>22</b>	<b>571</b>	<b>418</b>

## Appendix A: Consolidated statement of income by segment for 2013 (published)

In € millions (rounded)	2013							2012				
	Life	Life Generali US	Total Life	P&C	Group functions	Intra- Group	Total	Life	P&C	Group functions	Intra- Group	Total
Gross written premiums	5 196	209	5 405	4 848	0	0	10 253	4 864	4 650	0	0	9 514
Change in gross unearned premiums	-4	0	-4	-71	0	0	-75	3	-150	0	0	-147
Gross benefits and claims paid	-3 926	-161	-4 087	-2 967	0	0	-7 054	-3 780	-2 833	0	0	-6 613
Gross commissions on earned premiums	-875	-19	-894	-1 035	0	0	-1 929	-953	-956	0	0	-1 909
<b>Gross technical result</b>	<b>391</b>	<b>29</b>	<b>420</b>	<b>775</b>	<b>0</b>	<b>0</b>	<b>1 195</b>	<b>134</b>	<b>711</b>	<b>0</b>	<b>0</b>	<b>845</b>
Ceded written premiums	-563	-28	-591	-532	0	0	-1 123	-531	-445	0	0	-976
Change in ceded unearned premiums	0	0	0	11	0	0	11	0	8	0	0	8
Ceded claims	245	13	258	237	0	0	495	458	177	0	0	635
Ceded commissions	112	0	112	52	0	0	164	95	49	0	0	144
<b>Net result of retrocession</b>	<b>-206</b>	<b>-15</b>	<b>-221</b>	<b>-232</b>	<b>0</b>	<b>0</b>	<b>-453</b>	<b>22</b>	<b>-211</b>	<b>0</b>	<b>0</b>	<b>-189</b>
<b>Net technical result</b>	<b>185</b>	<b>14</b>	<b>199</b>	<b>543</b>	<b>0</b>	<b>0</b>	<b>742</b>	<b>156</b>	<b>500</b>	<b>0</b>	<b>0</b>	<b>656</b>
Other income and expenses from reinsurance operations	-12	0	-12	-56	0	0	-68	3	-39	0	0	-36
<b>Total other operating revenue / expenses</b>	<b>-12</b>	<b>0</b>	<b>-12</b>	<b>-56</b>	<b>0</b>	<b>0</b>	<b>-68</b>	<b>3</b>	<b>-39</b>	<b>0</b>	<b>0</b>	<b>-36</b>
Investment revenues	87	4	91	215	0	0	306	91	224	0	2	317
Interests on deposits	155	0	155	21	0	0	176	178	24	0	0	202
Realized capital gains / losses on investments	32	0	32	98	0	0	130	24	137	0	0	161
Change in investment impairment	-16	0	-16	-81	0	0	-97	-16	-70	0	0	-86
Change in fair value of investments	1	0	1	14	0	0	15	0	8	0	0	8
Foreign exchange gains/losses	-15	0	-15	5	0	0	-10	-2	25	0	0	23
<b>Investment income</b>	<b>244</b>	<b>4</b>	<b>248</b>	<b>272</b>	<b>0</b>	<b>0</b>	<b>520</b>	<b>275</b>	<b>348</b>	<b>0</b>	<b>2</b>	<b>625</b>
Investment management expenses	-10	0	-10	-21	-5	0	-36	-10	-15	-5	0	-30
Acquisition and administrative expenses	-177	-6	-183	-178	-12	0	-373	-165	-176	-8	0	-349
Other current operating income / expenses	-39	0	-39	-49	-67	0	-155	-45	-44	-88	0	-177
<b>Total other current income and expenses</b>	<b>-226</b>	<b>-6</b>	<b>-232</b>	<b>-248</b>	<b>-84</b>	<b>0</b>	<b>-564</b>	<b>-220</b>	<b>-235</b>	<b>-101</b>	<b>0</b>	<b>-556</b>
<b>Current operating results</b>	<b>191</b>	<b>12</b>	<b>203</b>	<b>511</b>	<b>-84</b>	<b>0</b>	<b>630</b>	<b>214</b>	<b>574</b>	<b>-101</b>	<b>2</b>	<b>689</b>
Other operating income / expenses	-4	0	-4	-45	0	0	-49	6	-50	0	0	-44
<b>Operating results before impact of acquisitions</b>	<b>187</b>	<b>12</b>	<b>199</b>	<b>466</b>	<b>-84</b>	<b>0</b>	<b>581</b>	<b>220</b>	<b>524</b>	<b>-101</b>	<b>2</b>	<b>645</b>
Loss ratio				64.1%					65.5%			
Commissions ratio				23.1%					22.3%			
P&C management expense ratio				6.7%					6.3%			
<b>Combined ratio<sup>1)</sup></b>				<b>93.9%</b>					<b>94.1%</b>			
<b>Life technical margin<sup>2)</sup></b>	<b>7.3%</b>	<b>7.7%</b>	<b>7.3%</b>					<b>7.7%</b>				

## Appendix A: SCOR Q4 2013 QTD financial details (published only)

in € millions (rounded)

		Q4 2013	Q4 2012	Variation at current FX	Variation at constant FX
<b>GROUP</b>	Gross written premiums	2 714	2 300	18.0%	23.3%
	Net earned premiums	2 407	2 068	16.4%	19.7%
	Operating results	329 <sup>5)</sup>	157	109.6%	
	Net income	247	100	147.0%	
	Group cost ratio <sup>1)</sup>	5.4%	5.9%	-0.6 pts	
	Investment income	128	155	-17.4%	
	Net return on invested assets w/o equity impairments <sup>2)</sup>	2.6%	3.7%	-1.1 pts	
	Net return on invested assets (with equity impairments) <sup>2)</sup>	2.6%	3.3%	-0.7 pts	
	Annualized ROE w/o equity impairments	21.5%	9.4% <sup>6)</sup>	12.1 pts	
	Annualized ROE	21.5%	8.8% <sup>6)</sup>	12.7 pts	
	EPS (€)	1.32	0.55	140.0%	
	Book value per share (€)	26.64	26.16 <sup>6)</sup>	1.8%	
	Operating cash flow	175	205	-14.7%	
<b>P&amp;C</b>	Gross written premiums	1 201	1 133	6.0%	12.3%
	Combined ratio <sup>3)</sup>	93.3%	95.0%	-1.7 pts	
<b>Life</b>	Gross written premiums	1 513	1 167	29.6%	33.9%
	Life technical margin <sup>4)</sup>	7.5%	9.0% <sup>4)</sup>	-1.5 pts	



1) See Appendix D, page 41 for detailed calculation of the cost ratio  
 2) See Appendix G, page 51 for detailed calculation of the return on invested assets  
 3) See Appendix E, page 43 for detailed calculation of the combined ratio  
 4) See Appendix F, page 46 for detailed calculation of the technical margin; the 2012 QTD technical margin contained 1 pt of non-recurring items (GMDB run-off portfolio reserve release)

5) Acquisition-related expenses and gain from bargain purchase are reported under "operating results before impact of acquisitions", to conform to the presentation within the 2013 "Document de Référence", see Appendix A, page 32  
 6) BVPS is adjusted due to the retrospective application of IAS 19 "revised", Q4 2012 published BVPS amounts to € 26.18, annualized ROE amounts to 8.7% and annualized ROE w/o equity impairments amounts to 9.4%

## Appendix A: Consolidated statement of income, Q4 2013 QTD (published)

<i>In € millions (rounded)</i>	<b>SCOR standalone</b>	<b>Generali US standalone</b>	<b>Q4 2013 Published</b>	<b>Q4 2012 Published</b>
Gross written premiums	2 505	209	2 714	2 300
Change in gross unearned premiums	-2	0	-2	39
Gross benefits and claims paid	-1 600	-161	-1 761	-1 645
Gross commissions on earned premiums	-473	-19	-492	-506
<b>Gross technical result</b>	<b>430</b>	<b>29</b>	<b>459</b>	<b>188</b>
Ceded written premiums	-247	-28	-275	-240
Change in ceded unearned premiums	-30	0	-30	-31
Ceded claims	-2	13	11	151
Ceded commissions	41	0	41	95
<b>Net result of retrocession</b>	<b>-238</b>	<b>-15</b>	<b>-253</b>	<b>-25</b>
<b>Net technical result</b>	<b>192</b>	<b>14</b>	<b>206</b>	<b>163</b>
Other income and expenses from reinsurance operations	-22	0	-22	0
<b>Total other operating revenue / expenses</b>	<b>-22</b>	<b>0</b>	<b>-22</b>	<b>0</b>
Investment revenues	76	4	80	84
Interests on deposits	44	0	44	53
Realized capital gains / losses on investments	23	0	23	44
Change in investment impairment	-10	0	-10	-17
Change in fair value of investments	6	0	6	2
Foreign exchange gains / losses	-11	0	-11	1
<b>Investment income</b>	<b>128</b>	<b>4</b>	<b>132</b>	<b>167</b>
Investment management expenses	-12	0	-12	-10
Acquisition and administrative expenses	-101	-6	-107	-93
Other current operating expenses	-30	0	-30	-54
Other current operating income	0	0	0	0
<b>Current operating results</b>	<b>155</b>	<b>12</b>	<b>167</b>	<b>173</b>
Other operating expenses	-16	0	-16	-15
Other operating income	2	0	2	3
<b>Operating results before impact of acquisitions</b>	<b>141</b>	<b>12</b>	<b>153</b>	<b>161</b>
Acquisition-related expenses	-2	-19	-21	-4
Gain on bargain purchase	0	197	197	0
<b>Operating results</b>	<b>139</b>	<b>190</b>	<b>329</b>	<b>157</b>
Financing expenses	-38	0	-38	-31
Share in results of associates	-14	0	-14	1
Corporate income tax	-32	3	-29	-27
<b>Consolidated net income</b>	<b>55</b>	<b>193</b>	<b>248</b>	<b>100</b>
of which non-controlling interests	-1	0	-1	0
<b>Group net income</b>	<b>54</b>	<b>193</b>	<b>247</b>	<b>100</b>



# Appendix A: Consolidated statement of income by segment for Q4 2013

## QTD, published

In € millions (rounded)	Q4 2013							Q4 2012				
	Life	Life Generali	Total Life	P&C	Group functions	Intra-Group	Total	Life	P&C	Group functions	Intra-Group	Total
Gross written premiums	1 304	209	1 513	1 201	0	0	2 714	1 167	1 133	0	0	2 300
Change in gross unearned premiums	-3	0	-3	1	0	0	-2	25	14	0	0	39
Gross benefits and claims paid	-860	-161	-1 021	-740	0	0	-1 761	-907	-738	0	0	-1 645
Gross commissions on earned premiums	-213	-19	-232	-260	0	0	-492	-261	-245	0	0	-506
<b>Gross technical result</b>	<b>228</b>	<b>29</b>	<b>257</b>	<b>202</b>	<b>0</b>	<b>0</b>	<b>459</b>	<b>24</b>	<b>164</b>	<b>0</b>	<b>0</b>	<b>188</b>
Ceded written premiums	-148	-28	-176	-99	0	0	-275	-152	-88	0	0	-240
Change in ceded unearned premiums	0	0	0	-30	0	0	-30	1	-32	0	0	-31
Ceded claims	-63	13	-50	61	0	0	11	92	59	0	0	151
Ceded commissions	28	0	28	13	0	0	41	83	12	0	0	95
<b>Net result of retrocession</b>	<b>-183</b>	<b>-15</b>	<b>-198</b>	<b>-55</b>	<b>0</b>	<b>0</b>	<b>-253</b>	<b>24</b>	<b>-49</b>	<b>0</b>	<b>0</b>	<b>-25</b>
<b>Net technical result</b>	<b>45</b>	<b>14</b>	<b>59</b>	<b>147</b>	<b>0</b>	<b>0</b>	<b>206</b>	<b>48</b>	<b>115</b>	<b>0</b>	<b>0</b>	<b>163</b>
Other income and expenses from reinsurance operations	-7	0	-7	-15	0	0	-22	5	-5	0	0	0
<b>Total other operating revenue / expenses</b>	<b>-7</b>	<b>0</b>	<b>-7</b>	<b>-15</b>	<b>0</b>	<b>0</b>	<b>-22</b>	<b>5</b>	<b>-5</b>	<b>0</b>	<b>0</b>	<b>0</b>
Investment revenues	23	4	27	53	0	0	80	21	61	0	2	84
Interests on deposits	41	0	41	3	0	0	44	47	6	0	0	53
Realized capital gains / losses on investments	6	0	6	17	0	0	23	4	40	0	0	44
Change in investment impairment	0	0	0	-10	0	0	-10	-1	-16	0	0	-17
Change in fair value of investments	0	0	0	6	0	0	6	0	2	0	0	2
Foreign exchange gains/losses	-18	0	-18	7	0	0	-11	-1	2	0	0	1
<b>Investment income</b>	<b>52</b>	<b>4</b>	<b>56</b>	<b>76</b>	<b>0</b>	<b>0</b>	<b>132</b>	<b>70</b>	<b>95</b>	<b>0</b>	<b>2</b>	<b>167</b>
Investment management expenses	-3	0	-3	-7	-2	0	-12	-4	-4	-2	0	-10
Acquisition and administrative expenses	-47	-6	-53	-51	-3	0	-107	-41	-50	-2	0	-93
Other current operating income / expenses	-8	0	-8	-10	-12	0	-30	-13	-9	-32	0	-54
<b>Total other current income and expenses</b>	<b>-58</b>	<b>-6</b>	<b>-64</b>	<b>-68</b>	<b>-17</b>	<b>0</b>	<b>-149</b>	<b>-58</b>	<b>-63</b>	<b>-36</b>	<b>0</b>	<b>-157</b>
<b>Current operating results</b>	<b>32</b>	<b>12</b>	<b>44</b>	<b>140</b>	<b>-17</b>	<b>0</b>	<b>167</b>	<b>65</b>	<b>142</b>	<b>-36</b>	<b>2</b>	<b>173</b>
Other operating income / expenses	-2	0	-2	-12	0	0	-14	-5	-7	0	0	-12
<b>Operating results before impact of acquisitions</b>	<b>30</b>	<b>12</b>	<b>42</b>	<b>128</b>	<b>-17</b>	<b>0</b>	<b>153</b>	<b>60</b>	<b>135</b>	<b>-36</b>	<b>2</b>	<b>161</b>
Loss ratio				63.2%					66.0%			
Commissions ratio				23.0%					22.8%			
P&C management expense ratio				7.1%					6.2%			
<b>Combined ratio<sup>1)</sup></b>				<b>93.3%</b>					<b>95.0%</b>			
<b>Life technical margin<sup>2)</sup></b>	<b>7.5%</b>	<b>7.7%</b>	<b>7.5%</b>					<b>9.0%<sup>3)</sup></b>				

1) See Appendix E, page 43 for detailed calculation of the combined ratio

2) See Appendix F, page 46 for detailed calculation of the technical margin

3) The 2012 QTD technical margin contains 1.0 pt of non-recurring items (GMDB run-off portfolio reserve release)

## Appendix A: Premiums at current and constant FX with Generali US

<i>In € millions (rounded)</i>	Q4'12 YTD	Q4'13 YTD Published	Q4'13 YTD Published at constant FX	Variation at current FX	Variation at constant FX
SCOR Global P&C	4 650	4 848	5 038	4.3%	8.3%
SCOR Global Life	4 864	5 196	5 359	6.8%	10.2%
Generali US		209	209		
<b>Total GWP as published</b>	<b>9 514</b>	<b>10 253</b>	<b>10 606</b>	<b>7.8%</b>	<b>11.5%</b>

## Appendix B: Accounting and transferred assets at the date of the Generali US acquisition

---

<i>In € millions (rounded)</i>	<b>2013</b>
<b>Assets</b>	
VOBA	453
Investments	867
Other assets <sup>1)</sup>	183
Cash and cash equivalents	583
<b>Total assets</b>	<b>2 086</b>
<b>Liabilities</b>	
Contract liabilities	1 046
Other liabilities	256
<b>Total Liabilities</b>	<b>1 302</b>
<b>Fair value of net assets</b>	<b>784</b>
<b>Consideration</b>	<b>587</b>
<b>Profit from a bargain purchase (badwill)</b>	<b>197</b>

- ❑ As of the acquisition date of 1 October 2013, Generali US has been fully consolidated by SCOR
- ❑ This results in recognition of VOBA of € 453 million and a profit from a bargain purchase (badwill) of € 197 million in the fourth quarter of 2013

## Appendix B: Consolidated balance sheet - Assets

<i>In € millions (rounded)</i>	2013	2012 Restated <sup>1)</sup>	2012 Published
<b>Intangible assets</b>	<b>2 307</b>	<b>1 941</b>	<b>1 941</b>
Goodwill	788	788	788
Value of business acquired	1 393	1 031	1 031
Other intangible assets	126	122	122
<b>Tangible assets</b>	<b>544</b>	<b>540</b>	<b>541</b>
<b>Insurance business investments</b>	<b>22 272</b>	<b>21 109</b>	<b>21 114</b>
Real estate investments	861	584	584
Available-for-sale investments	12 067	10 667	10 667
Investments at fair value through income	369	216	216
Loans and receivables	8 881	9 535	9 535
Derivative instruments	94	107	112
<b>Investments in associates</b>	<b>63</b>	<b>84</b>	<b>84</b>
<b>Share of retrocessionaires in insurance and investment contract liabilities</b>	<b>1 140</b>	<b>1 323</b>	<b>1 322</b>
<b>Other assets</b>	<b>6 321</b>	<b>6 213</b>	<b>6 122</b>
Deferred tax assets	813	689	688
Assumed insurance and reinsurance accounts receivable	4 179	4 242	4 205
Receivables from ceded reinsurance transactions	102	77	76
Taxes receivable	129	132	92
Other assets	190	263	251
Deferred acquisition costs	908	810	810
<b>Cash and cash equivalents</b>	<b>1 514</b>	<b>1 466</b>	<b>1 466</b>
<b>TOTAL ASSETS</b>	<b>34 161</b>	<b>32 676</b>	<b>32 590</b>

1) Certain prior year balance sheet items have been reclassified to be consistent with the current-year presentation

## Appendix B: Consolidated balance sheet – Liabilities & shareholders' equity

<i>In € millions (rounded)</i>	2013	2012 Restated <sup>1)</sup>	2012 Published
<b>Group shareholders' equity</b>	<b>4 940</b>	<b>4 800<sup>2)</sup></b>	<b>4 803</b>
Non-controlling interest	40	7	7
<b>Total shareholders' equity</b>	<b>4 980</b>	<b>4 807<sup>2)</sup></b>	<b>4 810</b>
<b>Financial debt</b>	<b>2 053</b>	<b>1 648</b>	<b>1 647</b>
Subordinated debt	1 379	1 212	1 212
Real estate financing <sup>3)</sup>	497	405	409
Other financial debt	177	31	26
<b>Contingency reserves</b>	<b>265</b>	<b>122</b>	<b>117</b>
<b>Contract liabilities</b>	<b>24 337</b>	<b>23 835</b>	<b>23 834</b>
Insurance contract liabilities	24 204	23 694	23 692
Investment contract liabilities	133	141	142
<b>Other liabilities</b>	<b>2 526</b>	<b>2 264</b>	<b>2 182</b>
Deferred tax liabilities	366	331	332
Derivative instruments	37	39	40
Assumed insurance and reinsurance payables	410	395	358
Accounts payable on ceded reinsurance transactions	988	890	888
Taxes payable	194	111	68
Other liabilities	531	498	496
<b>Total shareholders' equity &amp; liabilities</b>	<b>34 161</b>	<b>32 676</b>	<b>32 590</b>

1) Certain prior year balance sheet items have been reclassified to be consistent with the current year presentation


2) Shown SHE is adjusted in line with IAS 19 which had retrospective application, Q4 2012 published SHE amounts to € 4 810 million. The retroactive impact of IAS 19 on contingency reserves is € 5 million in Q4 2012. On Deferred tax liabilities, the impact is -€ 2 million

3) In 2012 it includes € 188 million used to finance buildings for own purposes which are classified under "Tangible assets" and € 186 million in 2013

## Appendix B: Consolidated statements of cash flows

<i>In € millions (rounded)</i>	<b>2013</b>	<b>2012</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>1 466</b>	<b>1 281</b>
<b>Net cash flows from operations</b>	<b>897</b>	<b>761</b>
Cash flow from changes in scope of consolidation	14	-3
Cash flow from acquisitions and sale of financial assets	-630	-361
Cash flow from acquisitions and disposals of tangible and intangible fixed assets	-50	-74
<b>Net cash flows from investing activities</b>	<b>-666</b>	<b>-438</b>
Transactions on treasury shares and issuance of equity instruments	-4	-56
Contingency capital	0	0
Dividends paid	-223	-203
<b>Cash flows from shareholder transactions</b>	<b>-227</b>	<b>-259</b>
Cash related to issue or reimbursement of financial debt	230	219
Interest paid on financial debt	-110	-106
<b>Cash flows from financing activities</b>	<b>120</b>	<b>113</b>
<b>Net cash flows from financing activities</b>	<b>-107</b>	<b>-146</b>
<b>Effect of changes in foreign exchange rates</b>	<b>-76</b>	<b>8</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>1 514</b>	<b>1 466</b>

# Appendix B: Net contract liabilities by segment (published)



## Appendix C: Calculations of EPS, book value per share and ROE, published

### Earnings per share calculation

<i>In € millions (rounded)</i>	2013	2012
Group net income <sup>1)</sup> (A)	549	418
Average number of opening shares (1)	192 384 219	192 021 303
Impact of new shares issued (2)	181 984	93 458
Time Weighted Treasury Shares (3)	-7 525 684	-8 273 802
Basic Number of Shares (B) = (1)+(2)+(3)	185 040 519	183 840 959
<b>Basic EPS (A)/(B)</b>	<b>2.96</b>	<b>2.28</b>

### Book value per share calculation

<i>In € millions (rounded)</i>	31/12/2013	31/12/2012
Group shareholders' equity (A)	4 940	4 800 <sup>2)</sup>
Shares issued at the end of the quarter (1)	192 757 911	192 384 219
Treasury Shares at the end of the quarter(2)	-7 343 237	-8 930 686
Basic Number of Shares (B) = (1)+(2)	185 414 674	183 453 533
<b>Basic Book Value PS (A)/(B)</b>	<b>26.64</b>	<b>26.16<sup>2)</sup></b>

### Post-tax Return on Equity (ROE)

<i>In € millions (rounded)</i>	2013	2012
Group net income <sup>1)</sup>	549	418
Opening shareholders' equity	4 800	4 400 <sup>2)</sup>
Weighted group net income <sup>3)</sup>	228	209
Payment of dividends	-148	-128
Weighted increase in capital	8	3
Effect of changes in foreign exchange rates <sup>3)</sup>	-81	-10
Revaluation of assets available for sale and other <sup>3)</sup>	-16	97
Weighted average shareholders' equity	4 791	4 571
<b>Annualized ROE</b>	<b>11.5%</b>	<b>9.1%<sup>2)</sup></b>

1) Excluding non-controlling interests

2) Shown SHE is adjusted due to the retrospective application of IAS 19 "revised". 2012 published SHE amounts to € 4 803 million, 2012 opening SHE published amounts € 4 403 million and 2013 published BVPS amounts to € 26.18. 2012 published weighted average shareholders' equity amounts to € 4 574 million. 2012 published annualized ROE 9.1%

3) 50% of the movement in the period



## Appendix D: Reconciliation of total expenses to cost ratio

<i>In € millions (rounded)</i>	<b>2013 Pro-forma</b>	<b>2013 Published</b>	<b>2012 Published</b>
<b>Total expenses as per Profit &amp; Loss account</b>	<b>-585</b>	<b>-565</b>	<b>-556</b>
ULAE (Unallocated Loss Adjustment Expenses)	-35	-34	-32
<b>Total management expenses</b>	<b>-620</b>	<b>-599</b>	<b>-588</b>
Investment management expenses	37	36	30
<b>Total expense base</b>	<b>-583</b>	<b>-563</b>	<b>-558</b>
Minus corporate finance	4	4	7
Minus amortization	31	31	27
Minus non-controllable expenses	9	9	24
<b>Total management expenses (for group cost ratio calculation)</b>	<b>-539</b>	<b>-519</b>	<b>-500</b>
Gross Written Premiums (GWP)	10 898	10 253	9 514
<b>Group cost ratio</b>	<b>5.0%</b>	<b>5.1%</b>	<b>5.3%</b>

## Appendix E: Key characteristics of SCOR Global P&C

### P&C steady growth


#### Gross Written Premiums

in € millions




### European focus with global presence

in %. Total € 4.8 billion



### SGPC business mix

in %. Total € 4.8 billion



- ❑ Underwrites **traditional reinsurance business focusing on short-tail business lines**, with a combination of local and global presence, **voluntarily underweight in the US** where it has a **selective approach**
- ❑ **Is a preferred partner for insurers and provides clients with customized solutions**, leveraging on franchise, network and a **global approach to synergies between specialty lines and treaty P&C**
- ❑ **Further develops alternative business platforms:** large corporate business platform (“Business Solutions”, Channel 2015 Lloyd’s Syndicate,
- ❑ **Uses cat capacity and retrocession as a strategic leverage tool**
- ❑ Combines pockets of growth with existing and new clients and stable technical profitability prospects, thanks to its **highly diversified portfolio** and **active portfolio management**
- ❑ **Managed to further improve its market position** during **successful January 2014 renewals**, benefiting from the “tiering” of the reinsurance market, and combining growth and profitability

## Appendix E: Calculation of P&C combined ratio

<i>In € millions (rounded)</i>	2013	2012
Gross earned premiums <sup>1)</sup>	4 777	4 500
Ceded earned premiums <sup>2)</sup>	-521	-437
<b>Net earned premiums (A)</b>	<b>4 256</b>	<b>4 063</b>
Gross benefits and claims paid	-2 967	-2 833
Ceded claims	237	177
Total net claims (B)	-2 730	-2 656
<b>Loss ratio (Net attritional + Natural catastrophes): -(B)/(A)</b>	<b>64.1%</b>	<b>65.5%</b>
Gross commissions on earned premiums	-1 035	-956
Ceded commissions	52	49
Total net commissions (C)	-983	-907
<b>Commission ratio: -(C)/(A)</b>	<b>23.1%</b>	<b>22.3%</b>
<b>Total technical ratio: -(B)+(C)/(A)</b>	<b>87.2%</b>	<b>87.8%</b>
Acquisition and administrative expenses	-178	-176
Other current operating income / expenses	-49	-44
Other income and expenses from reinsurance operations	-56	-39
<b>Total P&amp;C management expenses (D)</b>	<b>-283</b>	<b>-259</b>
<b>P&amp;C management expense ratio: -(D)/(A)</b>	<b>6.7%</b>	<b>6.3%</b>
<b>Total combined ratio: -(B)+(C)+(D)/(A)</b>	<b>93.9%</b>	<b>94.1%</b>

## Appendix E: Normalized net combined ratio

	QTD						YTD					
	1	2	3	4	5	1+2+3+5	1	2	3	4	5	1+2+3+5
	Published combined ratio	Reserves release	One off	Cat ratio	Cat ratio delta from 6% Cat budget	Normalized combined ratio	Published combined ratio	Reserves release	One off	Cat ratio	Cat ratio delta from 6% Cat budget	Normalized combined ratio
Q3 2009	97.3%			4.5%	1.5%	98.8%	97.4%			5.3%	0.7%	98.2%
Q4 2009	103.3%		-8.6% <sup>1)</sup>	4.7%	1.3%	96.0%	98.8%		-2.0% <sup>1)</sup>	5.1%	0.9%	97.7%
Q1 2010	108.6%			20.2%	-14.2%	94.4%	108.6%			20.2%	-14.2%	94.4%
Q2 2010	97.0%			6.0%	0.0%	97.0%	102.8%			13.1%	-7.1%	95.7%
Q3 2010	94.9%			6.2%	-0.2%	94.8%	99.9%			10.5%	-4.5%	95.4%
Q4 2010	95.8%			7.0%	-1.0%	94.8%	98.9%			9.6%	-3.6%	95.2%
Q1 2011	135.2%			46.3%	-40.3%	94.9%	135.2%			46.3%	-40.3%	94.9%
Q2 2011	92.6%		5.5% <sup>2)</sup>	6.6%	-0.6%	97.6%	113.1%		2.9% <sup>2)</sup>	25.7%	-19.7%	96.3%
Q3 2011	94.8%			5.9%	0.1%	95.0%	106.6%		1.8% <sup>2)</sup>	18.7%	-12.7%	95.8%
Q4 2011	98.4%	7.8% <sup>3)</sup>		17.8%	-11.8%	94.4%	104.5%	2.0% <sup>3)</sup>	1.4% <sup>2)</sup>	18.5%	-12.5%	95.4%
Q1 2012	92.5%			3.7%	2.3%	94.8%	92.5%			3.7%	2.3%	94.8%
Q2 2012	95.1%			5.2%	0.8%	95.9%	93.8%			4.5%	1.5%	95.3%
Q3 2012	93.6%			5.4%	0.6%	94.2%	93.7%			4.8%	1.2%	94.9%
Q4 2012	95.0%	8.8% <sup>4)</sup>		15.7%	-9.7%	94.1%	94.1%	2.2% <sup>4)</sup>		7.6%	-1.6%	94.7%
Q1 2013	90.4%			1.5%	4.5%	94.9%	90.4%			1.5%	4.5%	94.9%
Q2 2013	98.0%	2.9% <sup>5)</sup>		12.2%	-6.2%	94.7%	94.3%	1.5% <sup>5)</sup>		6.9%	-0.9%	94.9%
Q3 2013	93.7%			6.6%	-0.6%	93.1%	94.1%	1.0% <sup>5)</sup>		6.8%	-0.8%	94.3%
Q4 2013	93.3%			5.1%	0.9%	<b>94.2%</b>	93.9%	0.7% <sup>5)</sup>		6.4%	-0.4%	<b>94.2%</b>

1) Includes the outcome of the exceptional impact of the arbitration with Allianz in respect of the World Trade Center (€ 39 million after tax); the impact on the combined ratio is 8.6 pts on a quarterly basis and 2.0 pts on a YTD basis

2) Includes a € 47 million (pre-tax) positive effect (5.5 pts on a quarterly basis) related to settlement of the subrogation action undertaken by World Trade Center Property insurers against the Aviation insurers - on a YTD basis, the impact on the combined ratio is 2.9 pts at H1 2011, 1.8 pts at Q3 2011 and 1.4 pts at Q4 2011

3) Includes € 70 million (pre-tax) positive effect (7.8 pts on a quarterly basis) related to a reserve release in Q4 2011 – on a YTD basis, the impact on the combined ratio is 2.0 pts

4) Includes € 90 million (pre-tax) positive effect (8.8 pts on a quarterly basis) related to a reserve release in Q4 2012 – on a YTD basis, the impact on the combined ratio is 2.2 pts


5) Includes € 31 million (pre-tax) positive effect (2.9 pts on a quarterly basis) related to a reserve release in Q2 2013 – on a YTD basis, the impact on the combined ratio is 0.7 pts

## Appendix F: Key characteristics of SCOR Global Life

### Growing life base with biometric focus


#### Published gross written premiums

in € millions



### Geographically balanced book


in % of GWP  
Total € 5.4 billion



	Published	Pro-forma
North America	44%	50%
Latin America	7%	6%
Rest of Europe	13%	12%
France	10%	9%
Asia-Pacific	11%	10%
UK/Ireland	8%	8%
Germany	5%	5%
Middle East	2%	2%
Other	<1%	<1%

### Mortality-based portfolio

in % of GWP  
Total € 5.4 billion



	Published	Pro-forma
Life	65%	69%
Financing	11%	10%
Critical illness	5%	4%
Disability	5%	4%
Long-Term Care	3%	3%
Health	6%	6%
Personal accident	2%	2%
Longevity	3%	2%



- ❑ Focuses on traditional mortality reinsurance risks, providing stability of results, with **no underwriting of savings products** (variable or fixed annuities)
- ❑ Identifies three main business areas: traditional and innovative **protection** business, **longevity** covers, and a strong **financial solutions** offering
- ❑ Benefits from high barriers of entry
- ❑ Is optimally positioned to deliver relevant, tailor-made solutions to clients by combining:
  - **strong local presence**: on-the-ground teams, focusing on long-term relationships
  - **global centers of excellence**: actuarial, assessment and structuring expertise to understand and price biometric risks
- ❑ In October 2013, **acquired Generali US** and became **the market leader in US life reinsurance**<sup>1)</sup>
- ❑ Generates **significant amounts of free distributable cash flow** thanks to mature portfolio (more than € 1 billion since 2008)

## Appendix F: Calculation of the life technical margin

<i>In € millions (rounded)</i>	<b>SGL Standalone 2013</b>	<b>Generali US standalone 2013</b>	<b>SGL 2013 Published</b>	<b>SGL pro-forma 2013</b>	<b>SGL 2012</b>
Gross earned premiums <sup>1)</sup>	5 192	209	5 401	6 046	4 867
Ceded earned premiums <sup>2)</sup>	-563	-28	-591	-678	-531
<b>Net earned premiums (A)</b>	<b>4 629</b>	<b>181</b>	<b>4 810</b>	<b>5 368</b>	<b>4 336</b>
Net technical result	185	14	199	240	156
Interests on deposits	155	0	155	155	178
<b>Technical result (B)</b>	<b>340</b>	<b>14</b>	<b>354</b>	<b>395</b>	<b>334</b>
<b>Net technical margin (B)/(A)</b>	<b>7.3%</b>	<b>7.7%</b>	<b>7.3%<sup>3)</sup></b>	<b>7.4%</b>	<b>7.7%<sup>4)</sup></b>


1) Gross written premiums + Change in gross unearned premiums

2) Ceded gross written premiums + Change in ceded unearned premiums


3) The 2013 technical margin contains 0.1 pt of non-recurring items (GMDB run-off portfolio reserve release)

4) The 2012 technical margin contained 0.3 pts of non-recurring items (GMDB run-off portfolio reserve release)

# Appendix G: Investment portfolio asset allocation as of 31/12/2013



## Appendix G: Details of total investment portfolio





## Appendix G: Reconciliation of IFRS asset classification to IR presentation as of 31/12/2013

In € millions (rounded)

IFRS classification \ SGI classification	Cash	Fixed income	Loans	Equities	Real estate	Other investments	Total invested assets	Funds withheld by cedants	Total investments	Accrued interest	Technical items <sup>1)</sup>	Total IFRS classification
<b>Real estate investments</b>					<b>861</b>		<b>861</b>		<b>861</b>			<b>861</b>
Equities		57	47	343	126	161	734		734			734
Fixed income		10 893	334			2	11 229		11 229	104		11 333
<b>Available-for-sale investments</b>		<b>10 950</b>	<b>381</b>	<b>343</b>	<b>126</b>	<b>163</b>	<b>11 963</b>		<b>11 963</b>	<b>104</b>		<b>12 067</b>
Equities				108		214	322		322			322
Fixed income		46				0	46		46	1		47
<b>Investments at fair value through income</b>		<b>46</b>		<b>108</b>		<b>214</b>	<b>368</b>		<b>368</b>	<b>1</b>		<b>369</b>
<b>Loans and receivables</b>		<b>605</b>	<b>94</b>				<b>699</b>	<b>8 181</b>	<b>8 880</b>	<b>1</b>		<b>8 881</b>
<b>Derivative instruments</b>											<b>94</b>	<b>94</b>
<b>Total insurance business investments</b>		<b>11 601</b>	<b>475</b>	<b>451</b>	<b>987</b>	<b>377</b>	<b>13 891</b>	<b>8 181</b>	<b>22 072</b>	<b>106</b>	<b>94</b>	<b>22 272</b>
<b>Cash and cash equivalents</b>	<b>1 514</b>						<b>1 514</b>		<b>1 514</b>			<b>1 514</b>
<b>Total insurance business investments and cash and cash equivalents</b>	<b>1 514</b>	<b>11 601</b>	<b>475</b>	<b>451</b>	<b>987</b>	<b>377</b>	<b>15 405</b>	<b>8 181</b>	<b>23 586</b>	<b>106</b>	<b>94</b>	<b>23 786</b>
<b>Direct real estate URGL</b>					<b>112</b>		<b>112</b>		<b>112</b>			
<b>Direct real estate debt</b>					<b>- 311</b>		<b>- 311</b>		<b>- 311</b>			<b>- 311<sup>2)</sup></b>
<b>Cash payable/receivable</b>	<b>- 19<sup>3)</sup></b>						<b>- 19</b>		<b>- 19</b>			
<b>Total SGI classification</b>	<b>1 495</b>	<b>11 601</b>	<b>475</b>	<b>451</b>	<b>788</b>	<b>377</b>	<b>15 187</b>	<b>8 181</b>	<b>23 368</b>			

1) Including Atlas cat bonds and FX derivatives

2) Includes real estate financing and relates only to buildings owned for investment purposes

3) This relates to purchases of investments in December 2013 with normal settlement in January 2014

## Appendix G: Reconciliation of IFRS invested assets to IR presentation

<i>In € millions (rounded)</i>	Q4 2011	Q1 2012	Q2 2012	Q3 2012	Q4 2012	Q1 2013	Q2 2013	Q3 2013	Q4 2013
<b>IFRS invested assets</b>	<b>13 332</b>	<b>13 821</b>	<b>13 647</b>	<b>13 946</b>	<b>14 314</b>	<b>14 321</b>	<b>14 080</b>	<b>14 551</b>	<b>15 604</b>
<i>Accrued interest</i>	- 91	- 107	- 95	- 97	- 98	- 99	- 91	- 95	- 106
<i>Technical items<sup>1)</sup></i>	- 158	- 177	- 199	- 189	- 112	- 90	- 112	- 100	- 94
<i>Real estate URGL</i>	119	121	125	118	98	102	97	102	112
<i>Real estate debt<sup>2)</sup></i>	- 247	- 242	- 239	- 234	- 217	- 211	- 324	- 321	- 311
<i>Cash payable/receivable<sup>3)</sup></i>	0	- 316	- 1	- 19	- 3	36	- 63	70	- 19
<b>Invested assets in IR presentation</b>	<b>12 955</b>	<b>13 100</b>	<b>13 238</b>	<b>13 525</b>	<b>13 982</b>	<b>14 059</b>	<b>13 587</b>	<b>14 207</b>	<b>15 187</b>

## Appendix G: Details of investment returns

In € millions (rounded)

Annualized returns:	QTD 2012				2012	QTD 2013				2013
	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
Total net investment income <sup>1)</sup>	134	143	133	155	566	112	120	152	128	512
Average investments	20 697	20 985	21 208	21 501	21 098	21 662	21 289	21 300	22 543	21 698
<b>Return on Investments (ROI)</b>	<b>2.6%</b>	<b>2.8%</b>	<b>2.5%</b>	<b>2.9%</b>	<b>2.7%</b>	<b>2.1%</b>	<b>2.3%</b>	<b>2.9%</b>	<b>2.3%</b>	<b>2.4%</b>
<b>Return on invested assets<sup>2)</sup></b>	<b>2.9%</b>	<b>3.1%</b>	<b>2.6%</b>	<b>3.3%</b>	<b>3.0%</b>	<b>2.4%</b>	<b>2.6%</b>	<b>3.1%</b>	<b>2.6%</b>	<b>2.6%</b>
<i>Income</i>	2.1%	2.9%	1.9%	2.5%	2.3%	1.8%	2.6%	2.0%	2.0%	2.1%
<i>Realized capital gains/losses</i>	0.9%	1.0%	1.6%	1.3%	1.2%	1.3%	0.4%	1.3%	0.6%	0.9%
<i>Impairments &amp; real estate amortization</i>	-0.2%	-0.7%	-1.2%	-0.5%	-0.6%	-0.8%	-1.3%	-0.4%	-0.3%	-0.7%
<i>Fair value through income</i>	0.1%	0.0%	0.2%	0.1%	0.1%	0.1%	0.9%	0.1%	0.2%	0.3%
<b>Return on Invested Assets<sup>2)</sup> w/o equity impairments</b>	<b>3.0%</b>	<b>3.8%</b>	<b>3.6%</b>	<b>3.7%</b>	<b>3.5%</b>	<b>3.0%</b>	<b>3.7%</b>	<b>3.2%</b>	<b>2.6%</b>	<b>3.1%</b>
<b>Return on funds withheld</b>	<b>2.6%</b>	<b>2.5%</b>	<b>2.7%</b>	<b>2.7%</b>	<b>2.6%</b>	<b>2.0%</b>	<b>2.1%</b>	<b>3.0%</b>	<b>2.4%</b>	<b>2.3%</b>

## Appendix G: QTD Investment income development


In € millions (rounded)	QTD 2012				2012	QTD 2013				2013
	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3	Q4	FY
<b>Investment revenues on invested assets</b>	<b>69</b>	<b>95</b>	<b>69</b>	<b>84</b>	<b>317</b>	<b>64</b>	<b>91</b>	<b>71</b>	<b>80</b>	<b>306</b>
Realized gains/losses on fixed income	23	23	9	11	65	40	13	11	17	81
Realized gains/losses on loans	0	0	0	0	0	0	0	0	0	1
Realized gains/losses on equities	6	-1	2	2	10	6	4	4	4	18
Realized gains/losses on real estate	0	0	11	30	41	0	0	30	3	33
Realized gains/losses on other investments	0	12	32	1	45	0	-3	1	-1	-3
<b>Realized gains/losses on invested assets</b>	<b>29</b>	<b>33</b>	<b>55</b>	<b>44</b>	<b>161</b>	<b>46</b>	<b>14</b>	<b>47</b>	<b>23</b>	<b>130</b>
Change in impairment on fixed income	2	1	3	2	9	-2	-1	-1	0	-4
Change in impairment on loans	0	0	0	0	0	0	0	0	0	0
Change in impairment on equity	-5	-20	-33	-11	-69	-23	-39	-3	0	-64
Change in impairment/ amortization on real estate	-4	-5	-8	-9	-25	-4	-4	-6	-10	-24
Change in impairment on other investments	0	-1	-1	1	-1	0	-1	-4	0	-5
<b>Change in impairment on invested assets</b>	<b>-6</b>	<b>-24</b>	<b>-39</b>	<b>-17</b>	<b>-86</b>	<b>-29</b>	<b>-45</b>	<b>-13</b>	<b>-10</b>	<b>-97</b>
Fair value through income on invested assets	3	-1	6	3	12	4	30 <sup>1)</sup>	2	7	44 <sup>1)</sup>
Financing costs on real estate investments	-3	-2	-3	-2	-10	-2	-2	-2	-4	-11
<b>Total investment income on invested assets</b>	<b>92</b>	<b>101</b>	<b>88</b>	<b>112</b>	<b>394</b>	<b>83</b>	<b>88</b>	<b>105</b>	<b>96</b>	<b>372</b>
<b>Income on funds withheld</b>	<b>49</b>	<b>48</b>	<b>52</b>	<b>53</b>	<b>202</b>	<b>38</b>	<b>39</b>	<b>55</b>	<b>44</b>	<b>176</b>
Investment management expenses	-7	-6	-7	-10	-30	-9	-7	-8	-12	-36
<b>Total net investment income</b>	<b>134</b>	<b>143</b>	<b>133</b>	<b>155</b>	<b>566</b>	<b>112</b>	<b>120</b>	<b>152</b>	<b>128</b>	<b>512</b>
Foreign exchange gains / losses	7	4	11	1	23	-9	8	2	-11	-10
Income on technical items	0	0	-2	-1	-4	0	0	0	-1	-2
MRM badwill (net of acquisition costs)	0	0	0	0	0	0	-27	0	0	-27
Financing costs on real estate investments	3	2	3	2	10	2	2	2	4	11
<b>IFRS investment income net of investment management expenses</b>	<b>144</b>	<b>149</b>	<b>145</b>	<b>157</b>	<b>595</b>	<b>105</b>	<b>103</b>	<b>156</b>	<b>120</b>	<b>484</b>

1) Includes € 27m badwill (net of acquisition costs)

## Appendix G: Government bond portfolio as of 31/12/2013

### By region

In %. Total € 4.4 billion



### Top exposures

In € millions (rounded)


Q4 2013

USA	1 725
UK	811
Germany	390
Canada	304
France	237
Australia	176
Supranational <sup>1)</sup>	135
Japan	120
Netherlands	116
Republic of Korea	93
Singapore	78
Denmark	62
Belgium	55
South Africa	51
Austria	23
Hong Kong	17
Mexico	13
Others <sup>2)</sup>	18
<b>Total</b>	<b>4 423</b>

- No government bond exposure to Greece, Ireland, Italy, Portugal or Spain
- No exposure to US municipal bonds

## Appendix G: Corporate bond portfolio as of 31/12/2013

### By rating




### By sector/type

In € millions (rounded)	Q4 2013	In %
Consumer, Non-cyclical	1 018	22%
Financial	834	18%
Communications	510	11%
Industrial	458	10%
Consumer, Cyclical	457	10%
Energy	382	8%
Utilities	320	7%
Technology	279	6%
Basic materials	253	6%
Diversified / Funds	85	2%
Other	5	<1%
<b>Total</b>	<b>4 602</b>	<b>100%</b>


Source: Bloomberg sector definitions

### By region



Source: Bloomberg geography definitions

### By seniority




1) Including tier 1, upper tier 2 and tier 2 debts for financials

## Appendix G: Corporate bond portfolio as of 31/12/2013

<b>By seniority</b>								
<i>In € millions (rounded)</i>		<b>AAA</b>	<b>AA</b>	<b>A</b>	<b>BBB</b>	<b>Other<sup>1)</sup></b>	<b>Total</b>	<b>Market to Book Value %</b>
<b>Seniority</b>	Senior	86	820	2 064	921	426	4 317	101%
	Subordinated	0	0	8	58	10	77	104%
	Hybrid	0	0	11	76	105	192	106%
	Other	0	6	8	0	2	15	95%
<b>Total corporate bond portfolio</b>		<b>86</b>	<b>827</b>	<b>2 091</b>	<b>1 056</b>	<b>543</b>	<b>4 602</b>	<b>101%</b>



# Appendix G: “Financials” corporate bond portfolio as of 31/12/2013



**By sector** | In € millions (rounded)

	Q4 2013	In %
Bank	657	79%
Insurance	67	8%
Real estate	57	7%
Diversified financial services	53	6%
<b>Total</b>	<b>834</b>	<b>100%</b>

*Source: Bloomberg sector definitions*



**Top 10 exposures<sup>3)</sup>** | In € millions (rounded)

	31/12/2013
USA	283
France	168
Canada	87
Australia	71
Netherlands	50
Switzerland	47
Great Britain	39
Sweden	27
Italy	25
Germany	23
<b>Total</b>	<b>821</b>




1) AAA: 0.4%; NR:0.4%

2) Including tier 1, upper tier 2 and tier 2 debts for financials

3) These top 10 exposures represent 98% of total financial corporate bonds



## Appendix G: “Banks” financial corporate bond portfolio as of 31/12/2013



### Top 10 exposures<sup>3)</sup>

In € millions (rounded)

	31/12/2013
USA	221
France	97
Canada	77
Australia	70
Netherlands	44
Switzerland	39
Great Britain	35
Sweden	27
Italy	22
Germany	17
<b>Total</b>	<b>648</b>

1) AAA : 0.3%; NR : 0.1%

2) Including tier 1, upper tier 2 and tier 2 debts for financials

3) These top 10 exposures represent 99% of total “banks” financial corporate bonds

## Appendix G: Structured & securitized product portfolio as of 31/12/2013


<i>In € millions (rounded)</i>		AAA	AA	A	BBB	Other <sup>1)</sup>	Total	Market to Book Value %
<b>ABS</b>		16	9	2	0	0	27	103%
<b>CLO<sup>2)</sup></b>		68	1	0	0	4	72	100%
<b>CDO</b>		11	0	33	0	9	53	92%
<b>MBS</b>	CMO	0	0	1	2	16	20	100%
	Non-agency CMBS	20	3	0	0	2	25	107%
	Non-agency RMBS	176	3	12	1	5	198	101%
<b>Others</b>	Structured notes	5	0	59	7	13	85	97%
	Other	0	0	0	0	3	3	265%
<b>Total Structured &amp; Securitized Products<sup>3)</sup></b>		<b>295</b>	<b>17</b>	<b>107</b>	<b>11</b>	<b>52</b>	<b>481</b>	<b>100%</b>

## Appendix G: Loans portfolio as of 31/12/2013

<i>In € millions (rounded)</i>	Q4 2012	Q1 2013	Q2 2013	Q3 2013	Q4 2013
Infrastructure loans	0	0	0	20	49
Real estate loans <sup>1)</sup>	49	45	47	65	92
Corporate and leveraged loans <sup>2)</sup>	197	201	200	239	334
<b>Total</b>	<b>246</b>	<b>246</b>	<b>247</b>	<b>324</b>	<b>475</b>

## Appendix G: Equity portfolio as of 31/12/2013

<i>In € millions (rounded)</i>	Q4 2012	Q1 2013	Q2 2013	Q3 2013	Q4 2013
Common shares	529	505	457	312	288
Convex strategies <sup>1)</sup>	51	75	72	75	79
Convertible bonds	50	52	57	71	66
Preferred shares	21	20	20	19	18
<b>Total</b>	<b>651</b>	<b>653</b>	<b>606</b>	<b>477</b>	<b>451</b>



## Appendix G: Real estate portfolio as of 31/12/2013

<i>In € millions (rounded)</i>	<b>Q4 2012</b>	<b>Q1 2013</b>	<b>Q2 2013</b>	<b>Q3 2013</b>	<b>Q4 2013</b>
<b>Real estate securities and funds <sup>1)</sup></b>	115	119	123	121	126
<b>Direct real estate net of debt and including URGL</b>	465	518	664	653	662
<i>Direct real estate at amortized cost</i>	584	627	891	872	861
<i>Real estate URGL</i>	98	102	97	102	112
<i>Real estate debt</i>	-217	-211	-324	-321	-311
<b>Total</b>	<b>580</b>	<b>637</b>	<b>787</b>	<b>774</b>	<b>788</b>

## Appendix G: Other investments as of 31/12/2013

<i>In € millions (rounded)</i>	<b>Q4 2012</b>	<b>Q1 2013</b>	<b>Q2 2013</b>	<b>Q3 2013</b>	<b>Q4 2013</b>
Alternative investments <sup>1)</sup>	67	127	120	113	109
Non-listed equities	39	62	62	62	67
Commodities	37	36	24	25	0
Infrastructure funds	46	46	45	45	47
Private equity funds	12	12	12	13	13
Insurance Linked Securities (ILS)	80	82	84	85	141
<b>Total</b>	<b>281</b>	<b>364</b>	<b>347</b>	<b>342</b>	<b>377</b>

1) Excluding convex strategies categorized since Q3 2013 in the "Equity" portfolio, see Appendix G, page 60 for details

## Appendix G: Unrealized gains & losses development

<i>In € millions (rounded)</i>	<b>Q4 2012</b>	<b>Q1 2013</b>	<b>Q2 2013</b>	<b>Q3 2013</b>	<b>Q4 2013</b>	<b>Variance YTD</b>
Fixed income <sup>1)</sup>	203	195	20	53	12	-191
Loans	2	6	5	1	2	0
Equities	-71	-31	-1	23	35	107
Real estate <sup>2)</sup>	101	109	104	106	116	15
Other investments	-3	-2	1	5	6	8
<b>Total</b>	<b>232</b>	<b>276</b>	<b>129</b>	<b>188</b>	<b>171</b>	<b>-61</b>

## Appendix G: Reconciliation of asset revaluation reserve

<i>In € millions (rounded)</i>	31/12/2012	31/12/2013	Variance YTD
<b>Fixed income URGL</b>	<b>203</b>	<b>12</b>	<b>-191</b>
Of which:			
Government bonds & assimilated <sup>1)</sup>	24	-52	-75
Covered bonds & agency MBS	49	3	-45
Corporate bonds	134	61	-73
Structured & securitized products	-4	-2	2
<b>Loans URGL</b>	<b>2</b>	<b>2</b>	<b>0</b>
<b>Equities URGL</b>	<b>-71</b>	<b>35</b>	<b>107</b>
<b>Real estate funds URGL</b>	<b>4</b>	<b>5</b>	<b>1</b>
<b>Other investments URGL</b>	<b>-3</b>	<b>6</b>	<b>8</b>
<b>Invested assets URGL</b>	<b>232</b>	<b>171</b>	<b>-61</b>
Direct real estate <sup>2)</sup>	98	112	14
<b>Subtotal AFS URGL</b>	<b>135</b>	<b>59</b>	<b>-75</b>
<b>Gross asset revaluation reserve</b>	<b>135</b>	<b>59</b>	<b>-75</b>
Deferred taxes on revaluation reserve	-39	-16	23
Shadow accounting net of deferred taxes	-20	-1	20
Other <sup>3)</sup>	-10	-22	-12
<b>Total asset revaluation reserve</b>	<b>66</b>	<b>21</b>	<b>-45</b>

1) Including short-term investments

2) Direct real estate is included in the balance sheet at amortized cost. The unrealized gain on real estate presented here is the estimated amount that would be included in the balance sheet, were the real estate assets to be carried at fair value

3) Includes revaluation reserves (FX on equities AFS)



## Appendix H: Debt structure as of 31/12/2013

Type	Original amount issued	Current amount outstanding (book value)	Issue date	Maturity	Floating/ fixed rate	Coupon + step-up
Subordinated floating rate notes 30NC10	US \$ 100 million	US \$ 21 million	7 June 1999	30 years 2029	Floating	First 10 years: 3-month Libor rate + 0.80% and 1.80% thereafter
Subordinated floating rate notes 20NC10	€ 100 million	€ 94 million	6 July 2000	20 years July 2020	Floating	First 10 years: 3-month Euribor + 1.15% and 2.15% thereafter
Undated deeply subordinated fixed to floating rate notes PerpNC10	€ 350 million	€ 261 million	28 July 2006	Perpetual	Fixed	Initial rate at 6.154% p.a. until July 28, 2016, floating rate indexed on the 3-month Euribor + 2.90% margin
Undated subordinated fixed to floating rate notes PerpNC5.5	CHF 650 million	CHF 650 million	2 February 2011	Perpetual	Fixed	Initial rate at 5.375% p.a. until August 2, 2016, floating rate indexed to the 3-month CHF Libor + 3.7359% margin
Undated subordinated fixed to floating rate notes PerpNC5.7	CHF 315 million	CHF 315 million	8 October 2012	Perpetual	Fixed	Initial rate at 5.25% p.a. until June 8, 2018, floating rate indexed on the 3-month CHF Libor + 4.8167% margin
Undated subordinated fixed to floating rate notes PerpNC5.2	CHF 250 million	CHF 250 million	10 September 2013	Perpetual	Fixed	Initial rate at 5.00% p.a. until November 30 2018, floating rate indexed on the 3-month CHF Libor + 4.0992% margin

## Appendix I: Estimated sensitivity to interest rates and equity market

### Estimated sensitivity to interest rate & equity market movements on net income and shareholders' equity

<i>In € millions (rounded)</i>	<b>Net income<sup>2)3)</sup> 2013</b>	<b>Shareholders' equity<sup>2)3)</sup> impact 2013</b>	<b>Net income<sup>2)3)</sup> 2012</b>	<b>Shareholders' equity<sup>2)3)</sup> impact 2012</b>
Interest rates +100 points	13	(273)	10	(203)
<i>in % of shareholders' equity</i>	0.3%	(5.5)%	0.2%	(4.2)%
Interest rates -100 points	(13)	225	(10)	144
<i>in % of shareholders' equity</i>	(0.3)%	4.6%	(0.2)%	3.0%
Equity prices +10% <sup>1)</sup>	4	29	4	54
<i>in % of shareholders' equity</i>	0.1%	0.6%	0.1%	1.1%
Equity prices -10% <sup>1)</sup>	(5)	(29)	(15)	(54)
<i>in % of shareholders' equity</i>	(0.1)%	(0.6)%	(0.3)%	(1.1)%





SCOR conducted an analysis of the sensitivity of the impairment of equity securities, by applying the accounting policy and application guidance set out in Note 20.1.6.1 (H) to theoretical future market value changes. SCOR estimates that, excluding any impairment arising to duration, a further uniform decline of 10% from 31 December 2013 market values would generate a future further impairment of equity securities of € 1 million (2012: € 12 million). It should be noted that this figure should not be scaled up or down as the impairment rules are not a linear function of market value. For example a scenario with a market value decline of 20% would not double the potential further equity impairment

## Appendix I: Estimated sensitivity to FX movements

### Estimated sensitivity to FX movements on shareholders' equity

<i>In € millions (rounded)</i>	<b>FX movements</b>	<b>Shareholders' equity impact 2013</b>	<b>Shareholders' equity impact 2012</b>
USD/EUR	+10%	252	211
<i>in % of shareholders' equity</i>		5.1%	4.4%
USD/EUR	-10%	(252)	(211)
<i>in % of shareholders' equity</i>		(5.1)%	(4.4)%
GBP/EUR	+10%	33	33
<i>in % of shareholders' equity</i>		0.7%	0.7%
GBP/EUR	-10%	(33)	(33)
<i>in % of shareholders' equity</i>		(0.7)%	(0.7)%

# Appendix J: SCOR's rating has improved dramatically since 2005




### Legend

- ▲ Revios acquisition (11/06) ▲ Converium acquisition (08/07) ▲ TaRe acquisition (08/11) ▲ Generali US acquisition (10/13)
- ◻ Credit watch negative    ■ Stable outlook    + Positive outlook / cwp<sup>1)</sup>    x Issuer Credit Rating to "a+"

1) Credit watch with positive implications

# Appendix K: SCOR's exposure to emerging markets is optimized thanks to its robust currency and capital management


## SCOR has a worldwide franchise with a strong presence in emerging markets



- SCOR is a leading player in emerging markets, leveraging on the Group's network and capabilities
- Proven track record of strategic partnerships and reputation of knowledge transfer and services to cedants
- Geographical fragmentation requires specific expertise on regional and local regulation, accounting, tax and products
- SCOR practices rigorous currency matching between assets and liabilities, across the globe


## SCOR's GWP<sup>1)</sup> are largely in mature currencies and SCOR's capital<sup>2)</sup> risk to emerging markets is low

### Gross written premiums in emerging markets



- According to S&P definitions of emerging markets, SCOR writes approximately 12% of premiums in emerging market currencies

### Shareholders' equity by currencies



- SCOR has a highly efficient capital structure with more than 98% of its shareholders' equity in strong currencies

**SCOR exposure to emerging markets represents 3.0% of invested assets, of which c. 2.25% for ALM congruence reasons**

## Appendix K: SCOR executes its P&C strategy at 1/1 renewals, in line with projections released at the Monte Carlo rendez-vous and the assumptions of “Optimal Dynamics”

### SCOR Global P&C manages to further improve its market position in an increasingly discriminating market

#### Diversification and ability to lead are key success factors in an increasingly selective market

- ❑ **Tiering (or “bifurcation”)** of the **reinsurance market** continues, as insurers increasingly transact with fewer reinsurers
- ❑ **Market conditions are increasingly discriminating:** gap between leaders and followers and between multi-liners and narrower players is widening
- ❑ **SCOR’s diversified book, its combined franchise of treaty P&C and specialty lines and its leadership abilities are key drivers for differentiation**, with the global insurers’ initiative bearing fruit and showing growth despite restructuring and increased retentions

#### Sound premium growth while maintaining expected technical profitability quasi-stable

- ❑ **5% overall premium growth<sup>1)</sup>**, of which 3 pts due to the renewal of large quota-share deals in Asia
- ❑ **Profitability indicators are quasi-stable overall:** stable expected return on allocated capital, while expected gross U/W ratio increases by 0.9% and is almost neutralized on a net basis thanks to the savings made on retrocession costs
- ❑ **Overall pricing is quasi-stable at - 0.2%**, with variations in primary insurance prices partly compensating those of reinsurance rates. Terms and conditions under pressure but not materially deteriorating

#### In line with “Optimal Dynamics” hypothesis and targets

- ❑ **Business growth assumptions:**
  - **Reinsurance:** The 5% growth<sup>1)</sup> is broadly in line with “Optimal Dynamics” plan assumptions
  - **Lloyd’s:** The platform is building as expected (Channel 2015 and Lloyd’s capital provision business)
  - **SCOR Business Solutions:** growth in line with expectations, driven by specialty sectors and lines
- ❑ **Retrocession** programme according to plans, leading to a 0.6% expected positive impact on the net CR%

#### ❑ **Profitability:**

- 93%-94% “Optimal Dynamics” objective confirmed;
- 2014 net combined ratio expected within the range

#### ❑ **Growth:**

- 2014 gross written premiums are expected to reach approximately € 5 billion

# Appendix K: As alternative capital is complementary to the offer from first-tier reinsurers, SCOR takes advantage of the alternative capital market

## Clear differences between alternative capital and first-tier, diversified reinsurers...

### ❑ The alternative capital that has entered the reinsurance industry has clearly defined characteristics:

- Is a low cost model
- Offers collateralized capacity



### ❑ First-tier diversified reinsurers play an entirely different game

- Provide competitive pricing AND value added services to cedants (knowledge sharing, etc.)
- Make efficient use of capital (diversification) whilst having low counterparty risk
- Can underwrite all regions and perils
- Provide indemnity cover as a rule, not an exception: no basis risk issue
- Offer reinstatements cover and favour long-term relationships

## ...which SCOR uses to the advantage of its shareholders in terms of retrocession, offered services and asset management

### Optimized retrocession

- ❑ Reinsurers are users of alternative capital: 33% of alternative capital is backing reinsurers<sup>1)</sup>
- ❑ SCOR 1/1/14 renewals: 0.6% expected positive impact on net combined ratio from less expensive retrocession
- ❑ Broadened access to alternative capital market; issuance of extreme mortality transfer contracts at favourable conditions and formation of sidecar

### ILS services to clients

- ❑ SCOR is ready to help clients to access capital market capacity through ILS as a transformer
- ❑ SCOR offers expertise and basis risk coverage
- ❑ This generates fee income and allows SCOR to better leverage existing relationships (complementary to traditional reinsurance)

### Opening of ILS funds to 3rd parties by leveraging expertise

- ❑ SGI, regulated by the French AMF, provides external clients with access to innovative investment solutions in markets with high entry barriers
- ❑ SGI's ILS team manages 4 funds offering a range of products to 3<sup>rd</sup> party investors
- ❑ The funds target specific risk/return profile by investing in varying risk profiles of insurance risks

# Appendix K: SCOR's focus on franchise is a key competitive advantage for the Group in the current environment



Recent tiering in the P&C industry reinforces the competitive advantage of a **“Strong Franchise”** culture

**Longstanding and close partnership with clients across all markets** guaranteed by local presence: 37 offices worldwide

**Local people** facilitating the establishment of long-term relationships and the capacity to serve clients with full understanding of their needs

SCOR has established itself as a **leading player in emerging markets**, leveraging on the Group's network and capabilities, proven track record of strategic partnerships and reputation for knowledge transfer and services to cedants

**Local presence and growth in emerging markets have been increased** by recent opening in South Africa (2009), a SGL representative office in Mexico (2011), a SGPC office in Argentina (2012) and expanded presence in Brazil, in addition to well-established positions in China and India


SCOR was recently elected **“Most Popular Foreign-Capital Insurance Company”** in China<sup>1)</sup>

1) This award, received at the fifth China International Insurance Summit, comes at a time when the Group has considerably strengthened its positions in China and in the Asia-Pacific region. SCOR and the Chinese market share a long history based on the continuity of relationships developed over 40 years of cooperation, with permanent SCOR representatives in China for almost 15 years



## Appendix K: SCOR focuses on cost efficiency and productivity, while leading more than 15 internal projects to support its strategy

### SCOR continuously improves its cost efficiency whilst investing for the future



## Appendix L: SCOR's listing information

### Euronext Paris listing

SCOR's shares are publicly traded on the Eurolist by the Euronext Paris stock market

#### Main information

Valor symbol	SCR
ISIN	FR0010411983
Trading currency	EUR
Country	France

### SIX Swiss Exchange listing

SCOR's shares are publicly traded on the SIX Swiss Exchange (formerly known as the SWX Swiss Exchange)

#### Main information

Valor symbol	SCR
Valor number	2'844'943
ISIN	FR0010411983
Trading currency	CHF
Effective Date	August 8, 2007
Security segment	Foreign Shares

### ADR programme


SCOR's ADR shares trade on the OTC market

#### Main information

DR Symbol	SCRYY
CUSIP	80917Q106
Ratio	10 ADRs: 1 ORD
Country	France
Effective Date	June 5, 2007
Underlying SEDOL	B1LB9P6
Underlying ISIN	FR0010411983
U.S. ISIN	US80917Q1067
Depository	BNY Mellon

- SCOR's shares are also tradable over the counter on the Frankfurt Stock Exchange

# Appendix M: The strength of the SCOR group's strategy is recognized by industry experts



1) On November 21 2013, Standard & Poor's raised the outlook on the "A+" rating of SCOR SE and its main subsidiaries to "positive"